Skip to main content
Fig. 5 | Lipids in Health and Disease

Fig. 5

From: Apolipoprotein-A is a potential prognostic biomarker for severe aplastic anemia patients treated with ATG-based immunosuppressive therapy: a single-center retrospective study

Fig. 5

Overall survival (OS) and event free survival (EFS) based on serum Apo-A level. There was a significantly differences on EFS (P = 0.008, A) based on serum Apo-A level, but not OS (P = 0.202, B). The estimated 8.5-year EFS was 81.3% in group with Apo-A < 1.205 g/L and 44.9% in group with Apo-A ≥ 1.205 g/L; and the estimated 8.5-year OS was 83.4% and 77.0% in group with Apo-A < 1.205 g/L or ≥ 1.205 g/L, respectively

Back to article page